《新股消息》百勝中國(09987.HK)公開發售超購51倍 一手中籤率25%
百勝中國(09987.HK)公布來港第二上市的招股結果,發售價確定為每股412元,公開發售錄超購51.32倍,經重新分配後香港公開發售股份佔全球發售股份總數增至約16.5%;另國際發售獲超額認購約7.74倍。申請一手50股中籤比率僅為25%,要認購14手即700股才穩獲一手;該股將於明日(9月10日)在港上市。高盛(亞洲)為保薦人。
公司預計所得集資淨額為170.02億元,當中45%用於擴張及深化餐廳網絡;45%投資於數字化及供應鏈、食品創新及價值定位提升、優質資產;及10%用於運營資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.